Arnab Roy* 4
Mahesh Kumar Yadav 1
Ankit Kumar Srivastava 2
Madhu Vishwakarma 2
Juveriya Javed 2
Nitu Singh 2
Sudhanshu Shekhar 2
Gagan Gaykwad 2
Faizan Ansari 2
Sonu Kumar 2
Manu Kumar 2
Anchal Kumari 2
Deepika Kumari 2
Shyam Narayan 2
Ramesh Kumar 2
Naba Gorai 2
Ankita Singh 3
Meghna Singh 5
-
- Pandemic Context and Vaccine Imperative
The emergence of SARS-CoV-2 in late 2019 marked a pivotal moment in global health, sparking an extraordinary scientific response worldwide. Central to efforts to combat the pandemic was the rapid development of vaccines, which became a key strategy for controlling the spread of the virus and reducing its devastating impact. Among the countries that played a crucial role in this endeavor, India stood out for its significant contributions to vaccine research and development. India's approach was characterized by the mobilization of its indigenous scientific expertise and the adoption of innovative technologies, which collectively underscored the nation's ability to address major global health challenges. India’s vaccine development initiatives during the COVID-19 pandemic were multifaceted, with both public and private sectors actively collaborating to accelerate research and production. Notably, India leveraged its robust pharmaceutical industry, known for its large-scale production capabilities and experience in vaccine manufacturing, to ensure timely availability of vaccines. The country became a major player in vaccine development through partnerships with global organizations, such as the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI). Indian pharmaceutical companies, like Bharat Biotech and the Serum Institute of India, were at the forefront of developing and producing vaccines, including Covaxin and Covishield, respectively. These vaccines played a critical role not only in India's domestic immunization efforts but also in supplying doses to countries around the world, particularly low- and middle-income nations [1-5]. India’s ability to develop and distribute vaccines on a global scale showcased its growing prominence in biopharmaceutical innovation and its potential as a leader in addressing global health crises. The development of Covaxin, for instance, underscored the nation’s capacity for end-to-end vaccine development, from research and clinical trials to mass production and distribution. Covaxin, an inactivated virus vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), was one of the first vaccines to receive emergency use authorization in India. Similarly, the Serum Institute of India, which partnered with AstraZeneca and Oxford University to produce Covishield, highlighted the importance of international collaborations in accelerating vaccine availability. India’s vaccine diplomacy also became a significant aspect of its global response, with initiatives like the "Vaccine Maitri" (Vaccine Friendship) program enabling the country to provide millions of vaccine doses to neighboring and developing countries. This not only contributed to global efforts to control the pandemic but also strengthened India's geopolitical influence in global health diplomacy [6-11]. Therefore, India’s vaccine development during the COVID-19 pandemic exemplified the country's scientific and manufacturing capabilities, as well as its commitment to global health equity. The successful development and distribution of vaccines like Covaxin and Covishield not only helped mitigate the impact of the pandemic domestically but also positioned India as a key player in the global fight against COVID-19. This experience has further underscored the importance of investing in indigenous research and innovation to address future public health emergencies.
-
- Vaccine Platforms: A Comparative Overview
In India, two major vaccine platforms have played pivotal roles in combating the COVID-19 pandemic: the viral vector-based vaccine (Covishield) and the inactivated whole-virus vaccine (Covaxin). These technologies represent distinct approaches to eliciting immune responses and have significantly contributed to the country's vaccination drive. Covishield, developed by the Serum Institute of India in collaboration with AstraZeneca, employs a viral vector platform. This technology utilizes a modified version of a harmless adenovirus as a delivery system to introduce the genetic material encoding the spike protein of SARS-CoV-2 into human cells. Upon entering the cells, this genetic material instructs them to produce the spike protein, which subsequently triggers an immune response. The body generates neutralizing antibodies and activates cellular immunity, which together provide protection against the virus. Covishield's production is cost-effective and scalable, making it a vital component in India's vaccination strategy. It has demonstrated robust efficacy and safety profiles, thereby contributing to its widespread acceptance [12-15].
10.5281/zenodo.15518160